Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Non-Current Deffered Revenue: 2018

  • Northwest Biotherapeutics' Non-Current Deffered Revenue was N/A to $4.8 million in Q4 2018 from the same period last year, while for Dec 2018 it was $4.8 million, marking a year-over-year change of. This contributed to the annual value of $4.8 million for FY2018, which is N/A change from last year.
  • Northwest Biotherapeutics' Non-Current Deffered Revenue amounted to $4.8 million in Q4 2018.
  • Over the past 5 years, Northwest Biotherapeutics' Non-Current Deffered Revenue peaked at $4.8 million during Q4 2018, and registered a low of $4.8 million during Q4 2018.
  • For the 1-year period, Northwest Biotherapeutics' Non-Current Deffered Revenue averaged around $4.8 million, with its median value being $4.8 million (2018).